## EW: Edwards Lifesciences Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.5% below STRENGTH zone (3.0-6.0%); PEG 4.86 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($82.08)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 9
- **Sentiment:** Bullish (Bullish: 6, Bearish: 0)

**1. Edwards Lifesciences (NYSE: EW) targets 2026 EPS of $2.80-$2.95 with TMTT up 35%-45%**
- Source: Stock Titan | 20251204T140813 | Bullish | Relevance: 100%
- Edwards Lifesciences outlined its patient-focused strategy and financial guidance, projecting 2026 constant currency sales growth of 8%-10% to $6.4-$6.8 billion and adjusted EPS of $2.80-$2.95. The company expects significant growth in its Transcatheter Mitral and Tricuspid Therapies (TMTT) sales, targeting 35%-45% constant currency growth. Edwards is focusing on advancing structural heart therapies, including TAVR, TMTT, surgical innovations, and pioneering new areas like Structural Heart Failure and TAVR-AR.

**2. OMERS ADMINISTRATION Corp Boosts Stock Holdings in Edwards Lifesciences Corporation $EW**
- Source: MarketBeat | 20251203T124745 | Somewhat-Bullish | Relevance: 100%
- OMERS ADMINISTRATION Corp significantly increased its stake in Edwards Lifesciences Corporation (NYSE:EW) by 97.3%, acquiring an additional 21,950 shares. This boosted their total holdings to 44,504 shares valued at $3.48 million, contributing to institutional investors owning 79.46% of the stock. Meanwhile, company insiders have recently been selling shares, with the VP selling 1,020 shares and the CFO selling 13,000 shares.

**3. Edwards outlines strategy for sustained growth**
- Source: MassDevice | 20251204T202609 | Bullish | Relevance: 100%
- Edwards Lifesciences announced its strategy for sustained, differentiated growth entering 2026, reaffirming its 2025 guidance and projecting 8-10% sales growth and $2.80-$2.95 adjusted EPS for 2026. The company plans to expand its structural heart innovations to address aortic stenosis, mitral regurgitation, tricuspid regurgitation, and pulmonic diseases, as well as emerging opportunities like aortic regurgitation and structural heart failure. Key initiatives include advancing its TAVR platform, launching next-generation TMTT devices, and introducing the Triformis surgical valve.

**4. Edwards Lifesciences Corp. stock outperforms competitors on strong trading day**
- Source: MarketWatch | 20251204T165100 | Bullish | Relevance: 100%
- Edwards Lifesciences Corp. (EW) saw its stock advance 2.14% to $85.78, outperforming a mixed market session where the S&P 500 Index rose slightly and the Dow Jones Industrial Average fell. This gain broke a five-day losing streak for the company's shares.

**5. Edwards Lifesciences (EW) Revises FY25 Revenue Projection Upward**
- Source: GuruFocus | 20251204T150113 | Bullish | Relevance: 100%
- Edwards Lifesciences (EW) has updated its fiscal year 2025 financial outlook, projecting a revenue increase of 9% to 10% and showcasing strong financial health with robust margins. The company, a leader in medical devices specializing in structural heart disease treatments, provided this revised guidance at its annual investor conference. Despite positive analyst sentiment and strong financial indicators, a P/E ratio close to its 1-year high and recent insider selling activity suggest a mixed valuation picture.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-25 | BTIG | $100 | $100 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-25 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.00M) |
| Sells | 12 ($3.78M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 51.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 8 / 2 |

**Top Holders:**
- Vanguard Group Inc: 12.1% (+0.5%)
- Blackrock Inc.: 9.4% (-2.4%)
- JPMORGAN CHASE & CO: 8.6% (+87.2%)
- State Street Corpora: 4.4% (-0.1%)
- Wellington Managemen: 3.6% (+4.9%)

### Key Risks

1. Insider selling cluster: $3.8M in recent transactions.
2. Valuation stretched: PEG 4.9x requires aggressive growth execution.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 4.86 signals overvaluation risk, limited margin of safety. Forward P/E 29.9x stretched relative to 11% growth. Quality metrics strong (margin 23%). Balance sheet: strong liquidity (4.0x), low leverage (D/E 0.30). Insider selling cluster ($3.8M in 90 days), potential headwind. Institutional flow bullish (8 buying vs 2 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $51.0B |
| Beta | 0.97 |
| 52W Range | $65.94 - $87.89 |
| Short Interest | 1.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 4.86 |
| Forward P/E | 29.9 |
| Current P/E | 33.2 |
| YoY Growth | 11.1% |
| EPS Direction | STABLE |

### Technicals

MRS_10 stable at -1.5% (minimal 5-day change). Below STRENGTH zone by 4.5pp (needs >3.0% for momentum thesis). MRS_5 turning positive (0.1%) - potential reversal signal. Full SMA alignment bullish (above 20/50/200 SMAs). RSI neutral at 58. OFD pattern: +MTN (Rally).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.53% (CS: 37) | Neutral |
| RSI_14 | 57.8 | Neutral |
| MACD Histogram | -0.34 | Bearish |
| vs SMA20 | 1.008x | Above |
| vs SMA50 | 1.065x | Above |
| vs SMA200 | 1.119x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $85.78
- **Stop Loss:** $82.08 (4.3% risk)
- **Target:** $89.48 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 135
- **Position Value:** $11,580.30
- **Portfolio %:** 11.58%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-02-11 (Est: $0.62)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $0.59 | $0.67 | +12.6% |
| 2025Q2 | $0.62 | $0.67 | +7.6% |
| 2025Q1 | $0.60 | $0.64 | +7.5% |
| 2024Q4 | $0.55 | $0.59 | +6.4% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*